Bavencio
What Bavencio is used for
Bavencio is indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC). Bavencio in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). Bavencio is indicated as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum-based chemotherapy.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Bavencio
- Active substance
- avelumab
- Disease area
- Neuroendocrine Tumors
- Medicine group
- Other antineoplastic agents;Monoclonal antibodies
- ATC code
- L01FF04
- Marketing authorisation holder
- Merck Europe B.V.
- Authorised in the EU since
- 2017
Official information
In the USA
Same active substance: Bavencio
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Bavencio used for?
Bavencio is indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC). Bavencio in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). Bavencio is indicated as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum-based chemotherapy.
What is the active substance in Bavencio?
Bavencio contains avelumab.
Who makes Bavencio?
The EU marketing authorisation holder is Merck Europe B.V..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU